C16-PAF
CAS No. : 74389-68-7
(Synonyms: PAF (C16))
| Size | Price | Stock |
|---|---|---|
| 1mg | $54 | In-stock |
| 5mg | $120 | In-stock |
| 10mg | $210 | In-stock |
| 25mg | $465 | In-stock |
| 50mg | $745 | In-stock |
| 100mg | $1200 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-108635 |
| M.Wt: | 523.68 |
| Formula: | C26H54NO7P |
| Purity: | >98 % |
| Solubility: | H2O : 33.33 mg/mL (ultrasonic);DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C) |
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability[1][2][3][4][5]. In Vitro: C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) elicits significant concentration-dependent neuronal loss in PAFR / but not PAFR+/+ cultures. C16-PAF (1 μM) elicits neuronal death in PAFR / cells infected with EGFP alone[1].
C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR / neurons[1].
C16-PAF is synthesized by two distinct pathways; the remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor[2][3].
C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits M. smegmatis and M. bovis BCG growth in a time-dependent manner[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- C16-PAF
- Cat. No.:
- HY-108635
- Quantity:
Your information is safe with us.